Researchers from the Penn State College of Medicine developed a method to deliver a combination of drugs using nanoparticles in the hopes of preventing melanoma cancer cells from developing treatment-resistance. Their work was published in Molecular Cancer Therapeutics and Cancer Letters.
The team’s CelePlum-777 localized around cancer tumors and delivered a specific ratio of an anti-inflammatory, Celecoxib, and a toxin, Plumbagin, the researchers reported.
Get the full story at our sister site, Drug Delivery Business News.